Eli Lilly (NYSE: LLY) has been on a roll in recent years, thanks to its leadership in the weight management drug market.

True, Novo Nordisk is making progress in this field. It recently earned approval for an oral formulation of Wegovy, which ...

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...

Drugmakers Eli Lilly and Novo Nordisk have been sued in Texas by a compounding pharmacy that alleges they are illegally ...

Eli Lilly's research and development head said on Monday the company will have plenty of supply to launch its ...

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Novo Nordisk's Wegovy weight-loss pill has made an "encouraging" start after its launch this month, analysts said on Friday ...

At the J.P. Morgan Healthcare Conference, Nvidia announced major AI partnerships with Lilly and Thermo Fisher Scientific to ...